Comparison of healthcare resource use and cost between influenza and COVID-19 vaccine coadministration and influenza vaccination only
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Objective
To compare healthcare recourse utilizations (HCRU) and all-cause medical costs among individuals 50 years or older who received both influenza and COVID-19 vaccines on the same day and those that received influenza vaccine only
Methods
We conducted a retrospective cohort study leveraging Optum’s de-identified Clinformatics® DataMart from 8/31/2021 to 7/31/2023. Individuals 50 years or older continuously enrolled in health plans for one year prior and until 7/31/2023 were included in the study. Subjects were categorized into 2 cohorts based on their vaccination status between 8/31/2022 and 1/31/2023: receiving influenza and COVID-19 vaccine on same day (co-admin cohort) and receiving influenza vaccine only (influenza cohort). The association between vaccination status and all-cause, influenza-related, COVID-related, pneumonia-related, and cardiorespiratory-related hospitalization, as well as outpatient or emergency room visits and all-cause medical costs was estimated by weighted generalized linear models, adjusting for confounding by stabilized inverse probability of treatment weighting.
Results
613,156 (mean age: 71) and 1,340,011 (mean age: 72) individuals were included in the co-admin and influenza cohort respectively. After weighting, the baseline characteristics were balanced between cohorts. The co-admin cohort was at statistically significant lower risk of all-cause (RR: 0.95, 95%CI: 0.93-0.96), COVID-19-related (RR: 0.59, 95%CI: 0.56-0.63), cardiorespiratory-related (RR: 0.94, 95%CI: 0.93-0.96) and pneumonia-related (RR: 0.86, 95%CI: 0.83-0.90) hospitalization but not influenza-related hospitalizations (RR: 0.91, 95%CI: 0.81, 1.04) compared to influenza cohort. Co-administration was associated with 3% lower all-cause medical cost (cost ratio: 0.974, 95% CI: 0.968, 0.979) during the follow-up period compared to receiving influenza vaccine only.
Conclusion
Receiving both COVID-19 and influenza vaccines on the same day in comparison to receipt of influenza vaccine only was associated with reduced risk of HCRU, especially COVID-19 related hospitalization and all-cause medical costs. Interventions that increase vaccine coverage, particularly for COVID-19 might have public health and economic benefits.
